clinical trial · NCT06987968
A Study to See if an Investigational Medicine Called VS-01 Can Help and How Safe it is in the Treatment of Patients With Overt Hepatic Encephalopathy
Genfit·phase2·terminated·n = 3
Hepatic EncephalopathyAcute on Chronic Liver Failure (ACLF)Decompensated CirrhosisVS-01 on top of SOC (Active Treatment Group)SOC
brief summary
A Phase 2, Randomized, Controlled, Open-Label, Adaptive Dose Design, Proof-of-Concept Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Two Different Dwell Times of VS-01 on Top of Standard of Care versus Standard of Care Alone in Patients with Overt Hepatic Encephalopathy
started
Aug 25, 2025
primary completion
Sep 8, 2025
completion
Sep 15, 2025
last updated
Jan 12, 2026
official title
A Phase 2, Randomized, Controlled, Open-Label, Adaptive Dose Design, Proof-of-Concept Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Two Different Dwell Times of VS-01 on Top of Standard of Care Versus Standard of Care Alone in Patients With Overt Hepatic Encephalopathy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol